Distinct gut microbiome features characterize Fasciola hepatica infection and predict triclabendazole treatment outcomes in Peruvian patients

BackgroundFasciola hepatica, a globally distributed helminth, causes fasciolosis, a disease with significant health and economic impacts. Variability in triclabendazole (TCBZ) efficacy and emerging resistance are remaining challenges. Evidence suggests that the gut microbiome influences host-helmint...

Full description

Bibliographic Details
Published in:Frontiers in Cellular and Infection Microbiology
Main Authors: Giljae Lee, Bruce A. Rosa, Martha V. Fernandez-Baca, John Martin, Rodrigo A. Ore, Pedro Ortiz, Miguel M. Cabada, Makedonka Mitreva
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-03-01
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fcimb.2025.1555171/full
_version_ 1849747479181918208
author Giljae Lee
Bruce A. Rosa
Martha V. Fernandez-Baca
John Martin
Rodrigo A. Ore
Pedro Ortiz
Miguel M. Cabada
Miguel M. Cabada
Makedonka Mitreva
Makedonka Mitreva
Makedonka Mitreva
author_facet Giljae Lee
Bruce A. Rosa
Martha V. Fernandez-Baca
John Martin
Rodrigo A. Ore
Pedro Ortiz
Miguel M. Cabada
Miguel M. Cabada
Makedonka Mitreva
Makedonka Mitreva
Makedonka Mitreva
author_sort Giljae Lee
collection DOAJ
container_title Frontiers in Cellular and Infection Microbiology
description BackgroundFasciola hepatica, a globally distributed helminth, causes fasciolosis, a disease with significant health and economic impacts. Variability in triclabendazole (TCBZ) efficacy and emerging resistance are remaining challenges. Evidence suggests that the gut microbiome influences host-helminth interactions and is associated with anthelmintic effects, but its association with human F. hepatica infection and TCBZ efficacy is not well understood.MethodsIn this study, we investigated the relationship between Fasciola hepatica infection and the gut microbiome through metagenomic shotgun sequencing of 30 infected and 60 age- and sex-matched uninfected individuals from Peru. Additionally, we performed a longitudinal analysis to evaluate microbiome dynamics in relation to TCBZ treatment response.Results and discussionInfection was associated with specific microbial taxonomic and functional features, including higher abundance of Negativibacillus sp900547015, Blautia A sp000285855, and Prevotella sp002299635 species, and enrichment of microbial pathways linked to survival under stress and depletion of pathways for microbial growth. Unexpectedly, we identified that responders to TCBZ treatment (who cleared infection) harbored many microbiome features significantly different relative to non-responders, both before and after treatment. Specifically, the microbiomes of responders had a higher abundance Firmicutes A and Bacteroides species as well as phospholipid synthesis and glucuronidation pathways, while non-responders had higher abundance of Actinobacteria species including several from the Parolsenella and Bifidobacterium genera, and Bifidobacterium shunt and amino acid biosynthesis pathways.ConclusionsOur findings underscore the impact of helminth infection on gut microbiome and suggest a potential role of gut microbiota in modulating TCBZ efficacy, offering novel insights into F. hepatica-microbiome interactions and paving the way for microbiome-informed treatment approaches.
format Article
id doaj-art-e4898fba808b401b88a87ca470df1add
institution Directory of Open Access Journals
issn 2235-2988
language English
publishDate 2025-03-01
publisher Frontiers Media S.A.
record_format Article
spelling doaj-art-e4898fba808b401b88a87ca470df1add2025-08-20T01:40:41ZengFrontiers Media S.A.Frontiers in Cellular and Infection Microbiology2235-29882025-03-011510.3389/fcimb.2025.15551711555171Distinct gut microbiome features characterize Fasciola hepatica infection and predict triclabendazole treatment outcomes in Peruvian patientsGiljae Lee0Bruce A. Rosa1Martha V. Fernandez-Baca2John Martin3Rodrigo A. Ore4Pedro Ortiz5Miguel M. Cabada6Miguel M. Cabada7Makedonka Mitreva8Makedonka Mitreva9Makedonka Mitreva10Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United StatesDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United StatesDivision of Infectious Diseases, Department of Internal Medicine, The University of Texas Medical Branch, Galveston, TX, United StatesDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United StatesSede Cusco, Instituto de Medicina Tropical “Alexander von Humboldt”, Universidad Peruana Cayetano Heredia, Cusco, PeruFaculty of Veterinary Science, Universidad Nacional de Cajamarca, Cajamarca, PeruDivision of Infectious Diseases, Department of Internal Medicine, The University of Texas Medical Branch, Galveston, TX, United StatesSede Cusco, Instituto de Medicina Tropical “Alexander von Humboldt”, Universidad Peruana Cayetano Heredia, Cusco, PeruDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United StatesDepartment of Genetics, Washington University School of Medicine, St. Louis, MO, United StatesMcDonnell Genome Institute, Washington University in St. Louis, St. Louis, MO, United StatesBackgroundFasciola hepatica, a globally distributed helminth, causes fasciolosis, a disease with significant health and economic impacts. Variability in triclabendazole (TCBZ) efficacy and emerging resistance are remaining challenges. Evidence suggests that the gut microbiome influences host-helminth interactions and is associated with anthelmintic effects, but its association with human F. hepatica infection and TCBZ efficacy is not well understood.MethodsIn this study, we investigated the relationship between Fasciola hepatica infection and the gut microbiome through metagenomic shotgun sequencing of 30 infected and 60 age- and sex-matched uninfected individuals from Peru. Additionally, we performed a longitudinal analysis to evaluate microbiome dynamics in relation to TCBZ treatment response.Results and discussionInfection was associated with specific microbial taxonomic and functional features, including higher abundance of Negativibacillus sp900547015, Blautia A sp000285855, and Prevotella sp002299635 species, and enrichment of microbial pathways linked to survival under stress and depletion of pathways for microbial growth. Unexpectedly, we identified that responders to TCBZ treatment (who cleared infection) harbored many microbiome features significantly different relative to non-responders, both before and after treatment. Specifically, the microbiomes of responders had a higher abundance Firmicutes A and Bacteroides species as well as phospholipid synthesis and glucuronidation pathways, while non-responders had higher abundance of Actinobacteria species including several from the Parolsenella and Bifidobacterium genera, and Bifidobacterium shunt and amino acid biosynthesis pathways.ConclusionsOur findings underscore the impact of helminth infection on gut microbiome and suggest a potential role of gut microbiota in modulating TCBZ efficacy, offering novel insights into F. hepatica-microbiome interactions and paving the way for microbiome-informed treatment approaches.https://www.frontiersin.org/articles/10.3389/fcimb.2025.1555171/fullliver flukeFasciola hepaticatriclabendazoletreatment responseintestinal microbiomemetagenomic shotgun sequencing
spellingShingle Giljae Lee
Bruce A. Rosa
Martha V. Fernandez-Baca
John Martin
Rodrigo A. Ore
Pedro Ortiz
Miguel M. Cabada
Miguel M. Cabada
Makedonka Mitreva
Makedonka Mitreva
Makedonka Mitreva
Distinct gut microbiome features characterize Fasciola hepatica infection and predict triclabendazole treatment outcomes in Peruvian patients
liver fluke
Fasciola hepatica
triclabendazole
treatment response
intestinal microbiome
metagenomic shotgun sequencing
title Distinct gut microbiome features characterize Fasciola hepatica infection and predict triclabendazole treatment outcomes in Peruvian patients
title_full Distinct gut microbiome features characterize Fasciola hepatica infection and predict triclabendazole treatment outcomes in Peruvian patients
title_fullStr Distinct gut microbiome features characterize Fasciola hepatica infection and predict triclabendazole treatment outcomes in Peruvian patients
title_full_unstemmed Distinct gut microbiome features characterize Fasciola hepatica infection and predict triclabendazole treatment outcomes in Peruvian patients
title_short Distinct gut microbiome features characterize Fasciola hepatica infection and predict triclabendazole treatment outcomes in Peruvian patients
title_sort distinct gut microbiome features characterize fasciola hepatica infection and predict triclabendazole treatment outcomes in peruvian patients
topic liver fluke
Fasciola hepatica
triclabendazole
treatment response
intestinal microbiome
metagenomic shotgun sequencing
url https://www.frontiersin.org/articles/10.3389/fcimb.2025.1555171/full
work_keys_str_mv AT giljaelee distinctgutmicrobiomefeaturescharacterizefasciolahepaticainfectionandpredicttriclabendazoletreatmentoutcomesinperuvianpatients
AT brucearosa distinctgutmicrobiomefeaturescharacterizefasciolahepaticainfectionandpredicttriclabendazoletreatmentoutcomesinperuvianpatients
AT marthavfernandezbaca distinctgutmicrobiomefeaturescharacterizefasciolahepaticainfectionandpredicttriclabendazoletreatmentoutcomesinperuvianpatients
AT johnmartin distinctgutmicrobiomefeaturescharacterizefasciolahepaticainfectionandpredicttriclabendazoletreatmentoutcomesinperuvianpatients
AT rodrigoaore distinctgutmicrobiomefeaturescharacterizefasciolahepaticainfectionandpredicttriclabendazoletreatmentoutcomesinperuvianpatients
AT pedroortiz distinctgutmicrobiomefeaturescharacterizefasciolahepaticainfectionandpredicttriclabendazoletreatmentoutcomesinperuvianpatients
AT miguelmcabada distinctgutmicrobiomefeaturescharacterizefasciolahepaticainfectionandpredicttriclabendazoletreatmentoutcomesinperuvianpatients
AT miguelmcabada distinctgutmicrobiomefeaturescharacterizefasciolahepaticainfectionandpredicttriclabendazoletreatmentoutcomesinperuvianpatients
AT makedonkamitreva distinctgutmicrobiomefeaturescharacterizefasciolahepaticainfectionandpredicttriclabendazoletreatmentoutcomesinperuvianpatients
AT makedonkamitreva distinctgutmicrobiomefeaturescharacterizefasciolahepaticainfectionandpredicttriclabendazoletreatmentoutcomesinperuvianpatients
AT makedonkamitreva distinctgutmicrobiomefeaturescharacterizefasciolahepaticainfectionandpredicttriclabendazoletreatmentoutcomesinperuvianpatients